Market Overview

Report: uniQure Could Put Itself Up For Sale

Share:
Report: uniQure Could Put Itself Up For Sale

uniQure NV (NASDAQ: QURE) shares are trading higher by 6% in Monday's pre-market session following a Bloomberg report the company is exploring strategic options, including a potential sale.

uniQure is a gene therapy company exploring options amid interest from other pharmaceutical companies looking to expand in gene therapy.

The stock traded around $76.80 per share at time of publication after closing Friday at $72.55. The stock's 52-week higher is $78.02 and its 52-week low is $21.89.

Related Links:

6 Gene Therapy M&A Targets On The Radar

Sorrento Therapeutics Could IPO Its Scilex Unit

Posted-In: News Rumors Media

 

Related Articles (QURE)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Report: Apple Has Eye On Gold Statues With Movie Developments

Scoop: Shopify And ParcelPal To Integrate For Cannabis Delivery In Canada